{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T08:45:41Z","timestamp":1782722741669,"version":"3.54.5"},"reference-count":21,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","kidneymedicinejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Medicine"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.xkme.2026.101394","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:08:27Z","timestamp":1778285307000},"page":"101394","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dihydropyridine Calcium Channel Blocker Therapy and Risk of CKD Progression in Type 2 Diabetes Treated With Renin Angiotensin System Inhibitors and SGLT2 Inhibitors: A Real-World Retrospective Cohort Study"],"prefix":"10.1016","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8263-0900","authenticated-orcid":false,"given":"Timna","family":"Agur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tali","family":"Steinmetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shira","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"Zingerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Bielopolski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eviatar","family":"Nesher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ittai","family":"Fattal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eshcar","family":"Meisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benaya","family":"Rozen-Zvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xkme.2026.101394_bib1","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2215\/CJN.09510817","article-title":"Add-on antihypertensive medications to angiotensin-aldosterone system blockers in diabetes: a comparative effectiveness study","volume":"13","author":"Schroeder","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.xkme.2026.101394_bib2","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.kint.2023.05.024","article-title":"A nationwide cohort study comparing the effectiveness of diuretics and calcium channel blockers on top of renin-angiotensin system inhibitors on chronic kidney disease progression and mortality","volume":"104","author":"Faucon","year":"2023","journal-title":"Kidney Int"},{"key":"10.1016\/j.xkme.2026.101394_bib3","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.kint.2020.10.026","article-title":"Executive summary of the KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease","volume":"99","author":"Cheung","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.xkme.2026.101394_bib4","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1007\/s11606-024-08762-2","article-title":"Dihydropyridine calcium channel blockers and kidney outcomes","volume":"39","author":"Blum","year":"2024","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.xkme.2026.101394_bib5","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.kint.2022.08.012","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)","volume":"102","author":"de Boer","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.xkme.2026.101394_bib6","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting","volume":"384","author":"Dagan","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xkme.2026.101394_bib7","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12939-014-0115-1","article-title":"Is socioeconomic status associated with utilization of health care services in a single-payer universal health care system?","volume":"13","author":"Filc","year":"2014","journal-title":"Int J Equity Health"},{"key":"10.1016\/j.xkme.2026.101394_bib8","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/ndt\/gfz212","article-title":"Major adverse renal events (MARE): a proposal to unify renal endpoints","volume":"36","author":"Prischl","year":"2021","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.xkme.2026.101394_bib9","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s10157-021-02153-1","article-title":"Calcium channel blocker in patients with chronic kidney disease","volume":"26","author":"Ohno","year":"2022","journal-title":"Clin Exp Nephrol"},{"key":"10.1016\/j.xkme.2026.101394_bib10","doi-asserted-by":"crossref","first-page":"182","DOI":"10.2174\/1573402110666140131160617","article-title":"Renal microcirculation and calcium channel subtypes","volume":"9","author":"Homma","year":"2013","journal-title":"Curr Hypertens Rev"},{"key":"10.1016\/j.xkme.2026.101394_bib11","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000499486","article-title":"Consequences of glomerular hyperfiltration: the role of physical forces in the pathogenesis of chronic kidney disease in diabetes and obesity","volume":"143","author":"Chagnac","year":"2019","journal-title":"Nephron"},{"key":"10.1016\/j.xkme.2026.101394_bib12","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1046\/j.1523-1755.1999.00434.x","article-title":"Class differences in the effects of calcium channel blockers in the rat remnant kidney model","volume":"55","author":"Griffin","year":"1999","journal-title":"Kidney Int"},{"key":"10.1016\/j.xkme.2026.101394_bib13","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1172\/JCI112521","article-title":"Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension","volume":"77","author":"Zatz","year":"1986","journal-title":"J Clin Invest"},{"key":"10.1016\/j.xkme.2026.101394_bib14","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.xkme.2026.101394_bib15","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.xkme.2026.101394_bib16","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1001\/archinte.165.8.936","article-title":"Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"165","author":"Rahman","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.xkme.2026.101394_bib17","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0140-6736(09)62100-0","article-title":"Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial","volume":"375","author":"Bakris","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.xkme.2026.101394_bib18","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","article-title":"Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients","volume":"359","author":"Jamerson","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.xkme.2026.101394_bib19","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/ki.2008.102","article-title":"Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study","volume":"73","author":"Bakris","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.xkme.2026.101394_bib20","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","article-title":"SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control","volume":"17","author":"Cowie","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.xkme.2026.101394_bib21","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/hr.2016.85","article-title":"Dihydropyridine calcium channel blockers and renal disease","volume":"40","author":"Robles","year":"2017","journal-title":"Hypertens Res"}],"container-title":["Kidney Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059526001561?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059526001561?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T08:08:17Z","timestamp":1782720497000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590059526001561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2590059526001561"],"URL":"https:\/\/doi.org\/10.1016\/j.xkme.2026.101394","relation":{},"ISSN":["2590-0595"],"issn-type":[{"value":"2590-0595","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dihydropyridine Calcium Channel Blocker Therapy and Risk of CKD Progression in Type 2 Diabetes Treated With Renin Angiotensin System Inhibitors and SGLT2 Inhibitors: A Real-World Retrospective Cohort Study","name":"articletitle","label":"Article Title"},{"value":"Kidney Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xkme.2026.101394","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101394"}}